Previous 10 | Next 10 |
Gainers: Arrowhead Pharmaceuticals (NASDAQ: ARWR ) +47% . More news on: Arrowhead Pharmaceuticals, Inc., Eastman Kodak Company, Myomo, Inc., Stocks on the move, , Read more ...
Eastman Kodak Company (NYSE: KODK ) +42% as independent review says no laws were broken. More news on: Eastman Kodak Company, Myomo, Inc., Pacific Ethanol, Inc., Stocks on the move, , Read more ...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) jumps 10% on positive interim 24-week liver biopsy results in four subjects from AROAAT2002 , an open-label Phase 2 study of ARO-AAT, the second generation investigational RNA interference (RNAi) therapeutic being developed as a trea...
- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)...
One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology (NASDAQ: VIR) . The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. That substantially outperformed the ...
Arrowhead Pharmaceuticals ( ARWR ) is a clinical-stage company with a broad pipeline of therapies based on its TRiM RNAi platform. While Arrowhead seems some distance from having a commercial drug approval, it is working on a kind of therapy, RNAi, that other companies have successfully comm...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Oye Olukotun, M.D., MPH, as an independent director of the company, with a term beginning effective September 1, 2020. Douglass Given, M.D., Ph.D.,...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 15th Annual BioPharma Virtual Conference September 9, 2020 – Arrowhead management will participate in investor meetings Bai...
Eli Lilly offers positive data for Jardiance in treating cardiovascular issues Eli Lilly ( LLY ) reported positive data from EMPEROR-Reduced phase III trial. The study aimed to assess the potential of Jardiance in adults with heart failure with reduced ejection fraction, with and without...
The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiM TM ) platform. Eac...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may acc...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement ...